阴茎状细胞癌的全身化疗:机制,临床应用和基于证据的治疗方案
Michalina Grudzińska1, Mateusz Czajkowski2,3, Maciej Dolny2
1Student Scientific Circle, Department of Urology, Faculty of Medicine, Medical University of Gdańsk, Marii Skłodowskiej-Curie 3a, 80-210 Gdańsk, Poland.
对阴茎癌 (PSCC) 进行全身化疗至关重要,但证据有限. 目前的指导方针有利于cisplatin/taxane疗法,如TIP,由于毒性而避免白素,但需要更多的研究.
科学领域:
- 在瘤学瘤学.
- 医学化疗 医学化疗
- 罕见的癌症 罕见的癌症
背景情况:
- 阴茎状细胞癌 (PSCC) 是一种罕见且具有攻击性的恶性瘤.
- 系统化疗对于结节阳性或转移性PSCC至关重要.
- 支持化疗方案的证据主要来自小型的非随机化研究.
研究的目的:
- 分析用于PSCC治疗的细胞毒剂和疗法.
- 为了比较目前PSCC化疗的临床指南.
- 为PSCC管理的临床决策提供信息.
主要方法:
- 在PubMed,Scopus和Google Scholar的系统文献搜索.
- 报告客观反应,生存和毒性结果的优先研究.
- 包括对新辅助剂,辅助剂和息剂设置的分析,以及指导声明.
主要成果:
- 含有白胺的治疗方案显示有效,但高肺毒性导致停止治疗.
- 西斯/塔克桑组合 (TIP,TPF) 是当前的标准,TIP提供约40-50%的反应率.
- 对于不太适合的患者来说,PF或卡博普拉丁-纳双重剂是替代方案;应避免使用白素.
结论:
- 帕克利塔塞尔-异胺-西斯普拉丁 (TIP) 疗法是适合患者首选的新辅助疗法.
- 化疗双重剂适用于对西斯普拉丁耐受性有限的患者.
- 改善结果需要对这种罕见的癌症进行协调标准,生物标志物研究和多中心试验.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
06:11Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
相关概念视频
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Survival Analysis
Tumor Immunotherapy
